American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S1-S4 , December 2008

Introduction to “A Road Map for Intravenous Iron and Anemia Management: Preparing for the Future”

  • Daniel W. Coyne, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Daniel Coyne, MD, Washington University School of Medicine, 600 Euclid Ave, Campus Box 8129, St Louis, MO 63110

References 

  1. Deicher R, Zial F, Cohen G, Müllner M, Hörl W. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int. 2003;64:728–736
  2. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S11–S145
  3. US Renal Data System. USRDS 1996 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1996;
  4. National Kidney Foundation. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  5. Centers for Medicare & Medicaid Services. 2006 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Bethesda, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality; 2007;
  6. Centers for Medicare & Medicaid Services. 2005 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality; 2005;
  7. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  8. Drüeke TB, Locatelli F, Clyne N, et al. CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  9. Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  10. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  11. Leavitt MO. Secretary of Health and Human Services (Report to Congress: A Design for a Bundled End-Stage Renal Disease Prospective Payment System, 2008). http://www.cms.hhs.gov/ESRDGeneralInformation/Downloads/ESRDReportToCongress.pdfAccessed April 24, 2008
  12. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  13. Wish JB. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl. 2006;70:S21–S25
  14. Singh AK. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: What should we do now?. Am J Kidney Dis. 2008;52(suppl 1):S5–S13
  15. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htmAccessed February 25, 2008
  16. Centers for Medicare & Medicaid Services. CMS Manual System (Pub 100-04 Medicare Claims Processing. Transmittal 1307. Change Request 5700. 7-20-2007). http://www.cms.hhs.gov/Transmittals/Downloads/R1307CP.pdfAccessed January 3, 2008
  17. Coyne DW. A comprehensive vision for intravenous iron therapy. Am J Kidney Dis. 2008;52(suppl 1):S14–S20
  18. Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  19. Singh AK, Coyne DW, Shapiro W, Rizkala AR DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007;71:1163–1171
  20. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161–167
  21. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol. 1997;47:141–157
  22. Kapoian T. Challenge of effectively using erythropoiesis-stimulating agents and itravenous iron. Am J Kidney Dis. 2008;52(suppl 1):S21–S28
  23. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–379
  24. Pizzi LT. Economic considerations in a changing anemia environment. Am J Kidney Dis. 2008;52(suppl 1):S29–S33
  25. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am J Kidney Dis. 2007;50:471–530
  26. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  27. Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl. 2006;69:S13–S18
  28. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205–1210

 This article was published as part of a supplement sponsored by an educational grant from Watson Pharmaceuticals.

PII: S0272-6386(08)01303-6

doi: 10.1053/j.ajkd.2008.09.002

American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S1-S4 , December 2008

Article Tools